Plasma and stool metabolomic biomarkers of non-alcoholic fatty liver disease (nafld) in Argentina
- Autores
- Mazzini, Flavia; Cook, Frank; Gounarides, John; Marciano, Sebastian; Haddad, Leila; Tamaroff, Ana Jesica; Casciato, Paola; Narvaez, Adriana Haydée; Mascardi, María Florencia; Anders, Margarita; Orozco, F.; Quiroz, Nicolas; Risk, Marcelo; Gutt, Susana; Gadano, Adrián; Méndez García, Celia; Marro, Martin; Penas Steinhardt, Alberto; Trinks, Julieta
- Año de publicación
- 2020
- Idioma
- inglés
- Tipo de recurso
- documento de conferencia
- Estado
- versión publicada
- Descripción
- Non-invasive biomarkers are urgently needed to identify NAFLD patients at risk of progression to non-alcoholic steatohepatitis (NASH), particularly in high prevalence areas such as Latin America. Thus, we aimed to identify potential metabolomic biomarkers related to NAFLD stage in Argentina, and to assess their relationship with clinical and host genetic factors.Healthy volunteers (n=19) and biopsy-proven simple steatosis (n=12) or non-alcoholic steatohepatitis (n=22) patients with similar food intake data were recruited. Plasma and stool samples, as well as demographic and clinical data were collected. SNP rs738409 (PNPLA3 gene) was determined in all volunteers. HPLC and flow injection analysis with MS/MS in tandem was applied for metabolomic studies using the MxP Quant 500 Kit (Biocrates Life Sciences AG, Austria) and MetaboAnalyst v4.0. Bivariate and multivariate analyses identified variables independently related to NAFLD stage. Forward stepwise logistic regression models were constructed to diagnose NAFLD and NASH. ROC curves were used to evaluate models? accuracy.The concentration of 33 out of the 424 detected metabolites (25 in plasma and 8 in stool) significantly differed among groups. Levels of triglycerides (TG) were higher among NAFLD patients, whereas levels of phosphatidylcholines (PC) and lysoPC were lower among them. The PNPLA3 risk genotype was related to higher plasma levels of eicosenoic acid FA(20:1) (p<0.001). Plasma metabolites showed a higher accuracy for diagnosis of NAFLD and NASH (AUROC=1) than stool metabolites (AUROC=0.79 and 0.90, respectively). Body mass index and plasma levels of PC aa C24:0, FA(20:1) and TG(16:1_34:1) showed high accuracy for diagnosis of NAFLD (AUROC=1); whereas plasma levels of PC aa C24:0 and PC ae C40:1 showed AUROC=1 for discriminating NAFLD stages.In conclusion, potential metabolomic biomarkers for diagnosis and progression of NAFLD were identified in Argentina. Further validation studies are needed.
Fil: Mazzini, Flavia. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Hospital Italiano. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Instituto Universitario Hospital Italiano de Buenos Aires. Instituto de Medicina Traslacional E Ingenieria Biomedica.; Argentina
Fil: Cook, Frank. Novartis Institutes For Biomedical Research; Estados Unidos
Fil: Gounarides, John. Novartis Institutes For Biomedical Research; Estados Unidos
Fil: Marciano, Sebastian. Hospital Italiano; Argentina
Fil: Haddad, Leila. Hospital Italiano; Argentina
Fil: Tamaroff, Ana Jesica. Hospital Italiano; Argentina
Fil: Casciato, Paola. Hospital Italiano; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Narvaez, Adriana Haydée. Hospital Italiano; Argentina
Fil: Mascardi, María Florencia. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Hospital Italiano. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Instituto Universitario Hospital Italiano de Buenos Aires. Instituto de Medicina Traslacional E Ingenieria Biomedica.; Argentina
Fil: Anders, Margarita. Hospital Alemán; Argentina
Fil: Orozco, F.. Hospital Alemán; Argentina
Fil: Quiroz, Nicolas. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Hospital Italiano. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Instituto Universitario Hospital Italiano de Buenos Aires. Instituto de Medicina Traslacional E Ingenieria Biomedica.; Argentina
Fil: Risk, Marcelo. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Hospital Italiano. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Instituto Universitario Hospital Italiano de Buenos Aires. Instituto de Medicina Traslacional E Ingenieria Biomedica.; Argentina
Fil: Gutt, Susana. Hospital Italiano; Argentina
Fil: Gadano, Adrián. Hospital Italiano; Argentina
Fil: Méndez García, Celia. Novartis Institutes For Biomedical Research; Estados Unidos
Fil: Marro, Martin. Novartis Institutes For Biomedical Research; Estados Unidos
Fil: Penas Steinhardt, Alberto. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Lujan. Departamento de Cs.basicas. Laboratorio de Genomica Computacional.; Argentina
Fil: Trinks, Julieta. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Hospital Italiano. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Instituto Universitario Hospital Italiano de Buenos Aires. Instituto de Medicina Traslacional E Ingenieria Biomedica.; Argentina
LXV Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXVIII Reunión Anual de la Sociedad Argentina de Inmunología y Reunión Anual de la Sociedad Argentina de Fisiología
Argentina
Sociedad Argentina de Investigación Clínica
Sociedad Argentina de Inmunología
Sociedad Argentina de Fisiología - Materia
-
METABOLOME
NAFLD
NASH
ARGENTINA - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
.jpg)
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/154291
Ver los metadatos del registro completo
| id |
CONICETDig_580b65c064afaabc4e5569096619940e |
|---|---|
| oai_identifier_str |
oai:ri.conicet.gov.ar:11336/154291 |
| network_acronym_str |
CONICETDig |
| repository_id_str |
3498 |
| network_name_str |
CONICET Digital (CONICET) |
| spelling |
Plasma and stool metabolomic biomarkers of non-alcoholic fatty liver disease (nafld) in ArgentinaMazzini, FlaviaCook, FrankGounarides, JohnMarciano, SebastianHaddad, LeilaTamaroff, Ana JesicaCasciato, PaolaNarvaez, Adriana HaydéeMascardi, María FlorenciaAnders, MargaritaOrozco, F.Quiroz, NicolasRisk, MarceloGutt, SusanaGadano, AdriánMéndez García, CeliaMarro, MartinPenas Steinhardt, AlbertoTrinks, JulietaMETABOLOMENAFLDNASHARGENTINAhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Non-invasive biomarkers are urgently needed to identify NAFLD patients at risk of progression to non-alcoholic steatohepatitis (NASH), particularly in high prevalence areas such as Latin America. Thus, we aimed to identify potential metabolomic biomarkers related to NAFLD stage in Argentina, and to assess their relationship with clinical and host genetic factors.Healthy volunteers (n=19) and biopsy-proven simple steatosis (n=12) or non-alcoholic steatohepatitis (n=22) patients with similar food intake data were recruited. Plasma and stool samples, as well as demographic and clinical data were collected. SNP rs738409 (PNPLA3 gene) was determined in all volunteers. HPLC and flow injection analysis with MS/MS in tandem was applied for metabolomic studies using the MxP Quant 500 Kit (Biocrates Life Sciences AG, Austria) and MetaboAnalyst v4.0. Bivariate and multivariate analyses identified variables independently related to NAFLD stage. Forward stepwise logistic regression models were constructed to diagnose NAFLD and NASH. ROC curves were used to evaluate models? accuracy.The concentration of 33 out of the 424 detected metabolites (25 in plasma and 8 in stool) significantly differed among groups. Levels of triglycerides (TG) were higher among NAFLD patients, whereas levels of phosphatidylcholines (PC) and lysoPC were lower among them. The PNPLA3 risk genotype was related to higher plasma levels of eicosenoic acid FA(20:1) (p<0.001). Plasma metabolites showed a higher accuracy for diagnosis of NAFLD and NASH (AUROC=1) than stool metabolites (AUROC=0.79 and 0.90, respectively). Body mass index and plasma levels of PC aa C24:0, FA(20:1) and TG(16:1_34:1) showed high accuracy for diagnosis of NAFLD (AUROC=1); whereas plasma levels of PC aa C24:0 and PC ae C40:1 showed AUROC=1 for discriminating NAFLD stages.In conclusion, potential metabolomic biomarkers for diagnosis and progression of NAFLD were identified in Argentina. Further validation studies are needed.Fil: Mazzini, Flavia. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Hospital Italiano. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Instituto Universitario Hospital Italiano de Buenos Aires. Instituto de Medicina Traslacional E Ingenieria Biomedica.; ArgentinaFil: Cook, Frank. Novartis Institutes For Biomedical Research; Estados UnidosFil: Gounarides, John. Novartis Institutes For Biomedical Research; Estados UnidosFil: Marciano, Sebastian. Hospital Italiano; ArgentinaFil: Haddad, Leila. Hospital Italiano; ArgentinaFil: Tamaroff, Ana Jesica. Hospital Italiano; ArgentinaFil: Casciato, Paola. Hospital Italiano; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Narvaez, Adriana Haydée. Hospital Italiano; ArgentinaFil: Mascardi, María Florencia. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Hospital Italiano. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Instituto Universitario Hospital Italiano de Buenos Aires. Instituto de Medicina Traslacional E Ingenieria Biomedica.; ArgentinaFil: Anders, Margarita. Hospital Alemán; ArgentinaFil: Orozco, F.. Hospital Alemán; ArgentinaFil: Quiroz, Nicolas. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Hospital Italiano. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Instituto Universitario Hospital Italiano de Buenos Aires. Instituto de Medicina Traslacional E Ingenieria Biomedica.; ArgentinaFil: Risk, Marcelo. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Hospital Italiano. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Instituto Universitario Hospital Italiano de Buenos Aires. Instituto de Medicina Traslacional E Ingenieria Biomedica.; ArgentinaFil: Gutt, Susana. Hospital Italiano; ArgentinaFil: Gadano, Adrián. Hospital Italiano; ArgentinaFil: Méndez García, Celia. Novartis Institutes For Biomedical Research; Estados UnidosFil: Marro, Martin. Novartis Institutes For Biomedical Research; Estados UnidosFil: Penas Steinhardt, Alberto. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Lujan. Departamento de Cs.basicas. Laboratorio de Genomica Computacional.; ArgentinaFil: Trinks, Julieta. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Hospital Italiano. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Instituto Universitario Hospital Italiano de Buenos Aires. Instituto de Medicina Traslacional E Ingenieria Biomedica.; ArgentinaLXV Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXVIII Reunión Anual de la Sociedad Argentina de Inmunología y Reunión Anual de la Sociedad Argentina de FisiologíaArgentinaSociedad Argentina de Investigación ClínicaSociedad Argentina de InmunologíaSociedad Argentina de FisiologíaFundación Revista Medicina2020info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/conferenceObjectReuniónJournalhttp://purl.org/coar/resource_type/c_5794info:ar-repo/semantics/documentoDeConferenciaapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/154291Plasma and stool metabolomic biomarkers of non-alcoholic fatty liver disease (nafld) in Argentina; LXV Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXVIII Reunión Anual de la Sociedad Argentina de Inmunología y Reunión Anual de la Sociedad Argentina de Fisiología; Argentina; 2020; 1-50025-7680CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://inmunologia.org.ar/revista-medicina-2020/Nacionalinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:25:48Zoai:ri.conicet.gov.ar:11336/154291instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:25:48.345CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
| dc.title.none.fl_str_mv |
Plasma and stool metabolomic biomarkers of non-alcoholic fatty liver disease (nafld) in Argentina |
| title |
Plasma and stool metabolomic biomarkers of non-alcoholic fatty liver disease (nafld) in Argentina |
| spellingShingle |
Plasma and stool metabolomic biomarkers of non-alcoholic fatty liver disease (nafld) in Argentina Mazzini, Flavia METABOLOME NAFLD NASH ARGENTINA |
| title_short |
Plasma and stool metabolomic biomarkers of non-alcoholic fatty liver disease (nafld) in Argentina |
| title_full |
Plasma and stool metabolomic biomarkers of non-alcoholic fatty liver disease (nafld) in Argentina |
| title_fullStr |
Plasma and stool metabolomic biomarkers of non-alcoholic fatty liver disease (nafld) in Argentina |
| title_full_unstemmed |
Plasma and stool metabolomic biomarkers of non-alcoholic fatty liver disease (nafld) in Argentina |
| title_sort |
Plasma and stool metabolomic biomarkers of non-alcoholic fatty liver disease (nafld) in Argentina |
| dc.creator.none.fl_str_mv |
Mazzini, Flavia Cook, Frank Gounarides, John Marciano, Sebastian Haddad, Leila Tamaroff, Ana Jesica Casciato, Paola Narvaez, Adriana Haydée Mascardi, María Florencia Anders, Margarita Orozco, F. Quiroz, Nicolas Risk, Marcelo Gutt, Susana Gadano, Adrián Méndez García, Celia Marro, Martin Penas Steinhardt, Alberto Trinks, Julieta |
| author |
Mazzini, Flavia |
| author_facet |
Mazzini, Flavia Cook, Frank Gounarides, John Marciano, Sebastian Haddad, Leila Tamaroff, Ana Jesica Casciato, Paola Narvaez, Adriana Haydée Mascardi, María Florencia Anders, Margarita Orozco, F. Quiroz, Nicolas Risk, Marcelo Gutt, Susana Gadano, Adrián Méndez García, Celia Marro, Martin Penas Steinhardt, Alberto Trinks, Julieta |
| author_role |
author |
| author2 |
Cook, Frank Gounarides, John Marciano, Sebastian Haddad, Leila Tamaroff, Ana Jesica Casciato, Paola Narvaez, Adriana Haydée Mascardi, María Florencia Anders, Margarita Orozco, F. Quiroz, Nicolas Risk, Marcelo Gutt, Susana Gadano, Adrián Méndez García, Celia Marro, Martin Penas Steinhardt, Alberto Trinks, Julieta |
| author2_role |
author author author author author author author author author author author author author author author author author author |
| dc.subject.none.fl_str_mv |
METABOLOME NAFLD NASH ARGENTINA |
| topic |
METABOLOME NAFLD NASH ARGENTINA |
| purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.1 https://purl.org/becyt/ford/3 |
| dc.description.none.fl_txt_mv |
Non-invasive biomarkers are urgently needed to identify NAFLD patients at risk of progression to non-alcoholic steatohepatitis (NASH), particularly in high prevalence areas such as Latin America. Thus, we aimed to identify potential metabolomic biomarkers related to NAFLD stage in Argentina, and to assess their relationship with clinical and host genetic factors.Healthy volunteers (n=19) and biopsy-proven simple steatosis (n=12) or non-alcoholic steatohepatitis (n=22) patients with similar food intake data were recruited. Plasma and stool samples, as well as demographic and clinical data were collected. SNP rs738409 (PNPLA3 gene) was determined in all volunteers. HPLC and flow injection analysis with MS/MS in tandem was applied for metabolomic studies using the MxP Quant 500 Kit (Biocrates Life Sciences AG, Austria) and MetaboAnalyst v4.0. Bivariate and multivariate analyses identified variables independently related to NAFLD stage. Forward stepwise logistic regression models were constructed to diagnose NAFLD and NASH. ROC curves were used to evaluate models? accuracy.The concentration of 33 out of the 424 detected metabolites (25 in plasma and 8 in stool) significantly differed among groups. Levels of triglycerides (TG) were higher among NAFLD patients, whereas levels of phosphatidylcholines (PC) and lysoPC were lower among them. The PNPLA3 risk genotype was related to higher plasma levels of eicosenoic acid FA(20:1) (p<0.001). Plasma metabolites showed a higher accuracy for diagnosis of NAFLD and NASH (AUROC=1) than stool metabolites (AUROC=0.79 and 0.90, respectively). Body mass index and plasma levels of PC aa C24:0, FA(20:1) and TG(16:1_34:1) showed high accuracy for diagnosis of NAFLD (AUROC=1); whereas plasma levels of PC aa C24:0 and PC ae C40:1 showed AUROC=1 for discriminating NAFLD stages.In conclusion, potential metabolomic biomarkers for diagnosis and progression of NAFLD were identified in Argentina. Further validation studies are needed. Fil: Mazzini, Flavia. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Hospital Italiano. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Instituto Universitario Hospital Italiano de Buenos Aires. Instituto de Medicina Traslacional E Ingenieria Biomedica.; Argentina Fil: Cook, Frank. Novartis Institutes For Biomedical Research; Estados Unidos Fil: Gounarides, John. Novartis Institutes For Biomedical Research; Estados Unidos Fil: Marciano, Sebastian. Hospital Italiano; Argentina Fil: Haddad, Leila. Hospital Italiano; Argentina Fil: Tamaroff, Ana Jesica. Hospital Italiano; Argentina Fil: Casciato, Paola. Hospital Italiano; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Narvaez, Adriana Haydée. Hospital Italiano; Argentina Fil: Mascardi, María Florencia. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Hospital Italiano. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Instituto Universitario Hospital Italiano de Buenos Aires. Instituto de Medicina Traslacional E Ingenieria Biomedica.; Argentina Fil: Anders, Margarita. Hospital Alemán; Argentina Fil: Orozco, F.. Hospital Alemán; Argentina Fil: Quiroz, Nicolas. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Hospital Italiano. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Instituto Universitario Hospital Italiano de Buenos Aires. Instituto de Medicina Traslacional E Ingenieria Biomedica.; Argentina Fil: Risk, Marcelo. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Hospital Italiano. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Instituto Universitario Hospital Italiano de Buenos Aires. Instituto de Medicina Traslacional E Ingenieria Biomedica.; Argentina Fil: Gutt, Susana. Hospital Italiano; Argentina Fil: Gadano, Adrián. Hospital Italiano; Argentina Fil: Méndez García, Celia. Novartis Institutes For Biomedical Research; Estados Unidos Fil: Marro, Martin. Novartis Institutes For Biomedical Research; Estados Unidos Fil: Penas Steinhardt, Alberto. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Lujan. Departamento de Cs.basicas. Laboratorio de Genomica Computacional.; Argentina Fil: Trinks, Julieta. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Hospital Italiano. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Instituto Universitario Hospital Italiano de Buenos Aires. Instituto de Medicina Traslacional E Ingenieria Biomedica.; Argentina LXV Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXVIII Reunión Anual de la Sociedad Argentina de Inmunología y Reunión Anual de la Sociedad Argentina de Fisiología Argentina Sociedad Argentina de Investigación Clínica Sociedad Argentina de Inmunología Sociedad Argentina de Fisiología |
| description |
Non-invasive biomarkers are urgently needed to identify NAFLD patients at risk of progression to non-alcoholic steatohepatitis (NASH), particularly in high prevalence areas such as Latin America. Thus, we aimed to identify potential metabolomic biomarkers related to NAFLD stage in Argentina, and to assess their relationship with clinical and host genetic factors.Healthy volunteers (n=19) and biopsy-proven simple steatosis (n=12) or non-alcoholic steatohepatitis (n=22) patients with similar food intake data were recruited. Plasma and stool samples, as well as demographic and clinical data were collected. SNP rs738409 (PNPLA3 gene) was determined in all volunteers. HPLC and flow injection analysis with MS/MS in tandem was applied for metabolomic studies using the MxP Quant 500 Kit (Biocrates Life Sciences AG, Austria) and MetaboAnalyst v4.0. Bivariate and multivariate analyses identified variables independently related to NAFLD stage. Forward stepwise logistic regression models were constructed to diagnose NAFLD and NASH. ROC curves were used to evaluate models? accuracy.The concentration of 33 out of the 424 detected metabolites (25 in plasma and 8 in stool) significantly differed among groups. Levels of triglycerides (TG) were higher among NAFLD patients, whereas levels of phosphatidylcholines (PC) and lysoPC were lower among them. The PNPLA3 risk genotype was related to higher plasma levels of eicosenoic acid FA(20:1) (p<0.001). Plasma metabolites showed a higher accuracy for diagnosis of NAFLD and NASH (AUROC=1) than stool metabolites (AUROC=0.79 and 0.90, respectively). Body mass index and plasma levels of PC aa C24:0, FA(20:1) and TG(16:1_34:1) showed high accuracy for diagnosis of NAFLD (AUROC=1); whereas plasma levels of PC aa C24:0 and PC ae C40:1 showed AUROC=1 for discriminating NAFLD stages.In conclusion, potential metabolomic biomarkers for diagnosis and progression of NAFLD were identified in Argentina. Further validation studies are needed. |
| publishDate |
2020 |
| dc.date.none.fl_str_mv |
2020 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/conferenceObject Reunión Journal http://purl.org/coar/resource_type/c_5794 info:ar-repo/semantics/documentoDeConferencia |
| status_str |
publishedVersion |
| format |
conferenceObject |
| dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/154291 Plasma and stool metabolomic biomarkers of non-alcoholic fatty liver disease (nafld) in Argentina; LXV Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXVIII Reunión Anual de la Sociedad Argentina de Inmunología y Reunión Anual de la Sociedad Argentina de Fisiología; Argentina; 2020; 1-5 0025-7680 CONICET Digital CONICET |
| url |
http://hdl.handle.net/11336/154291 |
| identifier_str_mv |
Plasma and stool metabolomic biomarkers of non-alcoholic fatty liver disease (nafld) in Argentina; LXV Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXVIII Reunión Anual de la Sociedad Argentina de Inmunología y Reunión Anual de la Sociedad Argentina de Fisiología; Argentina; 2020; 1-5 0025-7680 CONICET Digital CONICET |
| dc.language.none.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://inmunologia.org.ar/revista-medicina-2020/ |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
| eu_rights_str_mv |
openAccess |
| rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
| dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf |
| dc.coverage.none.fl_str_mv |
Nacional |
| dc.publisher.none.fl_str_mv |
Fundación Revista Medicina |
| publisher.none.fl_str_mv |
Fundación Revista Medicina |
| dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
| reponame_str |
CONICET Digital (CONICET) |
| collection |
CONICET Digital (CONICET) |
| instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
| repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
| repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
| _version_ |
1844614257598005248 |
| score |
13.069144 |